A comprehensive discussion of the technologies being pursued, including tilmanocept.
You can download the whole article, but here are excerpts:
In a clinical trial, Zanni et al. used 99mTc-labeled tilmanocept as a method for visualizing macrophages in the vascular wall, which was administered to HIV-infected patients with imaging of its accumulation in the aortic wall . This RP is approved for use by the American Food Drug Administration (FDA) as an oncological imaging agent. Both in the described in vivo study and in experiments ex vivo, RP accumulation was demonstrated in areas with a high concentration of macrophages carrying the mannose receptor. The accumulation of RP in the aortic wall of HIV-infected individuals was higher (20.4% vs. 4.3% in the control group)
and corresponded mainly to the areas of non-calcified atherosclerotic plaques according to CT angiography .
...Among many radiopharmaceuticals reviewed in this article, the most promising ones are 111In-oxine and 99mTc-tilmanocept for SPECT and TSPO-targeted RPs for PET.
The presented data indicate an increasing interest in the results of molecular imaging with highly specific RPs, most likely associated with obtaining new information about the patterns and ways of implementing atherosclerosis as the main involutional process accompanying modern humans. Thus, nuclear medicine research, which is regarded today as hardly applicable in practice, can be reasonably recognized as one of the most advanced in modern biomedicine.